CTA1-DD is an effective adjuvant for targeting anti-chlamydial immunity to the murine genital mucosa

Agren, 1997, Genetically engineered nontoxic vaccine adjuvant that combines B cell targeting with immunomodulation by cholera toxin A1 subunit, J. Immunol., 158, 3936, 10.4049/jimmunol.158.8.3936 Akhiani, 2006, The nontoxic CTA1-DD adjuvant enhances protective immunity against Helicobacter pylori infection following mucosal immunization, Scand. J. Immunol., 63, 97, 10.1111/j.1365-3083.2005.01713.x Barker, 2008, In silico identification and in vivo analysis of a novel T-cell antigen from Chlamydia NrdB, Vaccine, 26, 1285, 10.1016/j.vaccine.2007.12.048 Beagley, 2000, Chlamydia trachomatis infection: incidence, health costs and prospects for vaccine development, J. Reprod. Immunol., 48, 47, 10.1016/S0165-0378(00)00069-3 Choi, 2002, The level of protection against rotavirus shedding in mice following immunization with a chimeric VP6 protein is dependent on the route and the coadministered adjuvant, Vaccine, 20, 1733, 10.1016/S0264-410X(02)00043-9 Cunningham, 2008, Poly-immunoglobulin receptor-mediated transport of IgA into the male genital tract is important for clearance of Chlamydia muridarum infection, Am. J. Reprod. Immunol., 60, 405, 10.1111/j.1600-0897.2008.00637.x Cunningham, 2008, Male genital tract chlamydial infection: implications for pathology and infertility, Biol. Reprod., 79, 180, 10.1095/biolreprod.108.067835 De Filette, 2006, The universal influenza vaccine M2e-HBc administered intranasally in combination with the adjuvant CTA1-DD provides complete protection, Vaccine, 24, 544, 10.1016/j.vaccine.2005.08.061 Eliasson, 2008, CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine, Vaccine, 26, 1243, 10.1016/j.vaccine.2007.12.027 Eriksson, 2004, The cholera toxin-derived CTA1-DD vaccine adjuvant administered intranasally does not cause inflammation or accumulate in the nervous tissues, J. Immunol., 173, 3310, 10.4049/jimmunol.173.5.3310 Fujihashi, 2002, A dilemma for mucosal vaccination: efficacy versus toxicity using enterotoxin-based adjuvants, Vaccine, 20, 2431, 10.1016/S0264-410X(02)00155-X Gallichan, 1998, Long-term immunity and protection against herpes simplex virus type 2 in the murine female genital tract after mucosal but not systemic immunization, J. Infect. Dis., 177, 1155, 10.1086/515286 Hickey, 2004, Intranasal immunization with C. muridarum major outer membrane protein (MOMP) and cholera toxin elicits local production of neutralising IgA in the prostate, Vaccine, 22, 4306, 10.1016/j.vaccine.2004.04.021 Igietseme, 2000, Induction of protective immunity against Chlamydia trachomatis genital infection by a vaccine based on major outer membrane protein-lipophilic immune response-stimulating complexes, Infect. Immun., 68, 6798, 10.1128/IAI.68.12.6798-6806.2000 Li, 2007, Induction of cross-serovar protection against genital chlamydial infection by a targeted multisubunit vaccination approach, Clin. Vaccine Immunol., 14, 1537, 10.1128/CVI.00274-07 McNeal, 2007, Intrarectal immunization of mice with VP6 and either LT(R192G) or CTA1-DD as adjuvant protects against fecal rotavirus shedding after EDIM challenge, Vaccine, 25, 6224, 10.1016/j.vaccine.2007.05.065 McNeilly, 2007, Expression library immunization confers partial protection against Chlamydia muridarum genital infection, Vaccine, 25, 2643, 10.1016/j.vaccine.2006.12.019 Mutsch, 2004, Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland, N. Engl. J. Med., 350, 896, 10.1056/NEJMoa030595 Pal, 2006, Immunization with the Chlamydia trachomatis major outer membrane protein, using adjuvants developed for human vaccines, can induce partial protection in a mouse model against a genital challenge, Vaccine, 24, 766, 10.1016/j.vaccine.2005.08.074 Peeling, 1996, Chlamydiae as pathogens: new species and new issues, Emerg. Infect. Dis., 2, 307, 10.3201/eid0204.960406 Stamm, 1999, Chlamydia trachomatis infections: progress and problems, J. Infect. Dis., 179, S380, 10.1086/513844 Sundling, 2008, CTA1-DD adjuvant promotes strong immunity against human immunodeficiency virus type 1 envelope glycoproteins following mucosal immunization, J. Gen. Virol., 89, 2954, 10.1099/vir.0.2008/005470-0